The leadership of the Congressional Diabetes Caucus is set to undergo a significant transition as Representative Kim Schrier (D-WA) prepares to assume the role of Democratic co-chair. Representative Schrier will officially take the helm in January 2027, following the conclusion of the 2026 election cycle in which the current co-chair, Representative Diana DeGette (D-CO), was not returned to office. Representative Gus Bilirakis (R-FL) is slated to continue his service as the Republican co-chair, maintaining the bipartisan leadership structure that has defined the caucus since its inception.
This leadership change marks a pivotal moment for one of the largest and most influential bicameral organizations in the United States Congress. Representative Schrier brings a unique combination of professional expertise and personal lived experience to the position. As the only pediatrician currently serving in Congress and the only member living with type 1 diabetes, her appointment is expected to provide a specialized clinical and patient-centric lens to federal diabetes policy. Schrier was diagnosed with type 1 diabetes at the age of 16, a factor that has frequently informed her legislative priorities regarding healthcare accessibility and chronic disease management.
A Legacy of Bipartisan Advocacy and Leadership Transition
The Congressional Diabetes Caucus serves as a platform for members of Congress to educate their colleagues and the public about the stresses of living with diabetes, while advocating for legislation that supports research, prevention, and treatment. The transition from Representative DeGette to Representative Schrier represents a passing of the torch between two figures who have prioritized healthcare throughout their careers.
Representative Diana DeGette has been a cornerstone of diabetes advocacy in Washington for over two decades. Her tenure as co-chair was marked by several legislative milestones, including the advancement of the 21st Century Cures Act and persistent efforts to address the rising costs of insulin. Under her leadership, the caucus grew into a robust bipartisan force capable of navigating complex budgetary and healthcare debates. Her departure at the end of the current term necessitates a leadership transition that ensures continuity in the caucus’s long-term goals, particularly regarding the reauthorization of critical federal programs.
Representative Schrier’s ascent to the co-chair position follows her active involvement in healthcare policy since her election in 2018. Representing Washington’s 8th Congressional District, Schrier has utilized her seat on the House Energy and Commerce Committee to advocate for lower prescription drug costs and improved pediatric health outcomes. Her transition into the caucus leadership is viewed by many stakeholders as a logical progression of her legislative focus.
The Profile of Representative Kim Schrier: Physician and Patient
Representative Schrier’s background provides a rare dual perspective in the halls of Congress. Before entering politics, she spent two decades practicing as a pediatrician in Issaquah, Washington. This clinical experience has allowed her to speak authoritatively on the challenges facing both healthcare providers and families managing chronic conditions.
Her personal diagnosis with type 1 diabetes as a teenager further informs her approach. Type 1 diabetes, an autoimmune condition where the pancreas produces little to no insulin, requires lifelong management through insulin injections or pumps and constant glucose monitoring. By navigating the complexities of the American healthcare system as a patient, Schrier has often highlighted the administrative and financial hurdles that can impede optimal care.
In her role as co-chair, Schrier is expected to leverage this expertise to address the specific needs of the diabetes community. This includes not only the biological aspects of the disease but also the socio-economic factors that influence health outcomes, such as food security, insurance coverage, and the availability of specialists in rural areas.
Legislative Priorities: Insulin Affordability and the Special Diabetes Program
The incoming leadership will face a demanding legislative agenda. Two of the most pressing priorities for the Congressional Diabetes Caucus remain the affordability of insulin and the sustained funding of the Special Diabetes Program (SDP).
Insulin affordability has become a central theme in national healthcare debates. While recent legislative efforts, such as the Inflation Reduction Act, have successfully capped the out-of-pocket cost of insulin at $35 for Medicare beneficiaries, a significant portion of the population—including those with private insurance and the uninsured—remains exposed to high costs. The caucus, under Schrier and Bilirakis, is expected to explore further avenues to extend these price protections across the entire commercial market and for those without coverage.
The Special Diabetes Program is another cornerstone of the caucus’s mission. Established in 1997, the SDP consists of two parts: the Special Statutory Funding Program for Type 1 Diabetes Research, administered by the National Institutes of Health (NIH), and the Special Diabetes Program for Indians (SDPI), administered by the Indian Health Service (IHS).
- Type 1 Research: The SDP provides $150 million annually for research aimed at preventing and curing type 1 diabetes. This funding has led to significant breakthroughs in artificial pancreas technology and immune therapies.
- SDPI: This program addresses the disproportionately high rates of type 2 diabetes among American Indian and Alaska Native populations. It has been credited with a 54% reduction in the incidence of end-stage renal disease among these communities.
The caucus must regularly advocate for the reauthorization of these programs to ensure that long-term research projects and community health initiatives are not disrupted by funding lapses.
Data and the Economic Burden of Diabetes in the United States
The urgency of the caucus’s work is underscored by the latest data from the Centers for Disease Control and Prevention (CDC) and the American Diabetes Association (ADA). As of the most recent reports, approximately 38.4 million Americans—nearly 11.6% of the population—have diabetes. Furthermore, an estimated 97.6 million adults aged 18 or older have prediabetes, a condition that significantly increases the risk of developing type 2 diabetes.
The economic impact of the disease is substantial. According to a 2023 study by the ADA, the total estimated cost of diagnosed diabetes in the U.S. is $412 billion annually. This includes:
- Direct Medical Costs: $306 billion spent on hospitalizations, medications, and supplies.
- Indirect Costs: $106 billion in reduced productivity, including disability, premature death, and work absenteeism.
On average, people with diagnosed diabetes have medical expenditures approximately 2.6 times higher than what expenditures would be in the absence of diabetes. These figures illustrate the high stakes of federal policy in this sector. For the Congressional Diabetes Caucus, the goal is to shift the trajectory of these costs through better prevention strategies and more efficient treatment models.
Stakeholder Responses and Professional Support
The announcement of Representative Schrier’s upcoming leadership has been met with positive responses from various medical and advocacy organizations. The Endocrine Society, a leading global organization representing endocrinologists and researchers, has expressed its support for the transition. The Society has a longstanding partnership with the caucus, collaborating on issues ranging from research funding to patient care standards.
In a statement following the announcement, representatives from the medical community noted that Schrier’s firsthand knowledge of the clinical environment is an asset. They emphasized the importance of having a leader who understands the daily realities of managing diabetes, particularly the nuances of pediatric care and the transition of care from childhood to adulthood.
Patient advocacy groups, such as JDRF (formerly the Juvenile Diabetes Research Foundation) and the American Diabetes Association, have also historically worked closely with the caucus co-chairs. These organizations rely on the caucus to champion the "Diabetes Agenda" on Capitol Hill, ensuring that the voices of the millions of Americans living with the condition are heard during the appropriations process and in the development of healthcare reform.
Broader Implications for Healthcare Policy in the 120th Congress
The shift in leadership comes at a time when the landscape of diabetes treatment is evolving rapidly. The emergence of new classes of medications, such as GLP-1 receptor agonists, has changed the management of type 2 diabetes and obesity, but it has also raised new questions regarding cost-benefit analyses and insurance coverage.
Representative Schrier’s tenure will likely involve navigating these technological and pharmaceutical advancements. Her role will require balancing the promotion of innovation with the necessity of ensuring that such innovations are accessible to all segments of the population. Furthermore, the bipartisan nature of the caucus will be essential in an increasingly polarized political environment. The partnership between Schrier and Bilirakis will be a critical factor in determining whether diabetes-related legislation can gain enough momentum to pass through both chambers of Congress.
The caucus is also expected to focus on the "hidden" aspects of diabetes, such as mental health support for those with chronic illnesses and the elimination of health disparities among minority populations. Data consistently shows that Black, Hispanic, and Indigenous populations experience higher rates of diabetes-related complications, such as amputations and kidney failure. Addressing these inequities is expected to be a key pillar of the caucus’s strategy moving forward.
Chronology of Leadership and Recent Developments
To understand the context of this transition, it is helpful to look at the recent timeline of the Congressional Diabetes Caucus and its leadership:
- 1990s: The caucus is founded to increase awareness and funding for diabetes.
- 2018: Kim Schrier is elected to Congress, bringing her experience as a pediatrician to the House.
- 2021-2024: Representative DeGette and Representative Bilirakis lead the caucus through the COVID-19 pandemic, highlighting the increased risks faced by individuals with diabetes during the public health crisis.
- 2024: Representative DeGette loses her re-election bid, triggering the need for a new Democratic co-chair.
- November 2024: Representative Schrier is identified as the successor to DeGette.
- January 2027: Representative Schrier will formally assume the co-chair position at the start of the new Congress.
This timeline reflects a period of stability followed by a significant shift, providing an opportunity for the caucus to refine its mission under new leadership.
Conclusion and Future Outlook
As the 120th Congress approaches, the appointment of Representative Kim Schrier as Democratic co-chair of the Congressional Diabetes Caucus signals a commitment to evidence-based policy and patient-centered advocacy. With the continued partnership of Representative Gus Bilirakis, the caucus remains positioned to address the multifaceted challenges of the diabetes epidemic.
The transition period between now and January 2027 will allow for a strategic handover of responsibilities, ensuring that the momentum generated by Representative DeGette’s years of service is maintained. For the millions of Americans living with diabetes, the leadership of a physician-patient like Schrier offers the prospect of a legislative agenda deeply rooted in the realities of the disease, aiming for a future defined by better treatments, increased research funding, and ultimately, a cure.
